Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

HLB's liver cancer drug back under FDA review, with decision due in April |

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at koreabiomed.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

HLB's liver cancer drug combination CAM-RIVO has been resubmitted for FDA approval with a decision expected by April 9, 2027, following positive phase 3 trial results indicating significant survival benefits.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clear regulatory path opening April 2027 if you build liver cancer treatments in biotech. This FDA review restart signals a near-term chance to access US market with improved survival data.

◆ Coverage

1 source · 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechliver-cancerFDA-approvalclinical-trialsdrug-resubmissionbiotech